Source: Eur Respir Rev 2015; 25: 19-28
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Gillespie Stephen H.. The role of moxifloxacin in tuberculosis therapy. Eur Respir Rev 2015; 25: 19-28

Member's Comments

No comment yet.

Related content which might interest you: A study of role of rifabutin as an adjuvant in management of cases with multi-drug resistant pulmonary tuberculosis Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis Year: 2007 A study on the clinical efficacy of a combination regimen with azithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 722s Year: 2004 Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006 Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy Source: Eur Respir J 2001; 17: 641-646 Year: 2001 Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017 In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis Source: Eur Respir J 2014; 44: 808-811 Year: 2014 Clinical efficacy and safety of clarithromycin in the treatment of multi-drug resistant tuberculosis Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 What is the optimal dosage of linezolid in treatment of complicated multidrug-resistant tuberculosis? Source: Eur Respir J 2009; 34: 1492-1494 Year: 2009 High-dose rifampicin and rifapentine in tuberculosis treatment Source: International Congress 2015 – Tuberculosis: short-course chemotherapy Year: 2015 Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013 Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Source: Eur Respir J 2011; 38: 888-894 Year: 2011 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease Source: Eur Respir J 2015; 45: 1177-1179 Year: 2015 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007